Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Fineline Cube Jul 3, 2026
Company Drug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Fineline Cube Jul 3, 2026
Company Medical Device

P-Cure Initiates Construction of Affordable Proton Therapy Center in China’s Shandong Province

Fineline Cube Jan 2, 2024

P-Cure, an Israeli company specializing in proton therapy, has commenced construction on a proton therapy...

Company Deals

Medilink Therapeutics Secures Multi-Billion Dollar Deal with Roche for c-MET Targeting ADC

Fineline Cube Jan 2, 2024

Medilink Therapeutics, a Suzhou-based biopharmaceutical company, has entered into a global collaboration and licensing agreement...

Company Deals

Beijing Avistone Pharmaceuticals Raises RMB 1 Billion in Series B Funding to Accelerate Drug Development

Fineline Cube Dec 29, 2023

Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd, based in China, has successfully closed its Series B...

Company Drug

Boan Biotech Secures FDA Orphan Drug Designations for Pancreatic Cancer Treatments

Fineline Cube Dec 29, 2023

China-based Boan Biotech (HKG: 6955) has announced that its novel antibody BA1105 and antibody-drug conjugate...

Company Deals

Eli Lilly Teams Up with Fauna Bio to Uncover New Anti-Obesity Drug Targets

Fineline Cube Dec 29, 2023

Eli Lilly (NYSE: LLY) has entered a collaboration agreement with fellow U.S. firm Fauna Bio...

Company Drug

Gilead’s Kite Receives FDA Nod to Add Overall Survival Data to Yescarta for Large B-Cell Lymphoma

Fineline Cube Dec 29, 2023

Gilead Sciences Inc. (NASDAQ: GILD) subsidiary Kite has received approval from the U.S. Food and...

Company Drug

FDA Prioritizes Roche’s Xolair for Food Allergy Indication Extension Ahead of Q1 Decision

Fineline Cube Dec 29, 2023

The U.S. Food and Drug Administration (FDA) has prioritized Roche’s (SWX: ROG) indication extension filing...

Company Drug

Lepu Biotechnology Completes Enrollment for Phase IIb Trial of MRG003 in Nasopharyngeal Carcinoma

Fineline Cube Dec 29, 2023

Lepu Biotechnology Co., Ltd (HKG: 2157), based in China, has announced the completion of subject...

Company Medical Device

Sino Medical Secures Approvals for Key Coronary Devices in Taiwan, India, and Uzbekistan

Fineline Cube Dec 29, 2023

Sino Medical Sciences Technology Inc. (SHA: 688108), a China-based medical device company, has announced that...

Company Drug

Shanghai Henlius Secures Indonesian Approval for HanSiZhuang in Small-Cell Lung Cancer

Fineline Cube Dec 29, 2023

Shanghai Henlius Biotech Inc. (HKG: 2696) has received market approval from the Indonesian Food and...

Company Deals

IVD Medical Ends Strategic Partnership with Japan’s Sysmex in Coagulation Products

Fineline Cube Dec 29, 2023

IVD Medical Holding Ltd (HKG: 1931), a China-based in vitro diagnostic (IVD) specialist, has announced...

Company Drug

Clover Biopharma’s SCB-219M Shows Promising Phase I Results for Chemotherapy-Induced Thrombocytopenia

Fineline Cube Dec 29, 2023

Clover Biopharmaceuticals Ltd (HKG: 2197), based in China, has announced promising preliminary results from its...

Company Deals

Eli Lilly Completes Acquisition of Point Biopharma, Expanding Radiopharmaceutical Portfolio

Fineline Cube Dec 28, 2023

Eli Lilly (NYSE: LLY) has finalized its acquisition of radiopharmaceutical company Point Biopharma (NASDAQ: PNT)...

Company Drug

Fosun’s HLX42 Receives Fast-Track Designation from FDA for NSCLC Treatment

Fineline Cube Dec 28, 2023

Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196; SHA: 600196) has announced that its antibody-drug conjugate...

Company Deals

CATUG Biotechnology Partners with PersonGen to Advance Global CAR-T Cell Therapies

Fineline Cube Dec 28, 2023

China-based CATUG Biotechnology (Suzhou) Co., Ltd. has entered into a partnership with fellow Suzhou firm...

Company Medical Device

Cryofocus Medtech Secures NMPA Approval for Cryotherapy Equipmen

Fineline Cube Dec 28, 2023

Shanghai-based Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922) has announced that it has received marketing...

Company Drug

Simcere Secures Approval for Local Manufacturing of Cosela, Boosting Patient Access

Fineline Cube Dec 28, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has received supplementary filing approval for its drug Cosela...

Company

Chengda Pharmaceuticals Halts Shanghai Research Project Amid Market Challenges

Fineline Cube Dec 28, 2023

Chengda Pharmaceuticals Co. Ltd. (SHE: 301201), based in China, has announced the termination of its...

Company Deals

TYK Medicines Secures Nearly RMB 200 Million in Series D Financing Led by Sichuan Huiyu Pharmaceutical

Fineline Cube Dec 28, 2023

Shanghai-based TYK Medicines (HKG: 2410) has successfully completed a Series D financing round, raising nearly...

Company Medical Device

NMPA Approves Pulnovo Medical’s Novel Catheter for Treating Pulmonary Arterial Hypertension

Fineline Cube Dec 28, 2023

The National Medical Products Administration (NMPA) has granted marketing approval for Pulnovo Medical’s disposable circular...

Posts pagination

1 … 447 448 449 … 690

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes
  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody
  • CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Company Drug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Company Drug

Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.